...
首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Noninvasive Prenatal Diagnosis of Duchenne Muscular Dystrophy: Comprehensive Genetic Diagnosis in Carrier, Proband, and Fetus
【24h】

Noninvasive Prenatal Diagnosis of Duchenne Muscular Dystrophy: Comprehensive Genetic Diagnosis in Carrier, Proband, and Fetus

机译:杜氏肌营养不良的非侵入性产前诊断:携带者,先证者和胎儿的综合遗传学诊断。

获取原文
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Noninvasive prenatal diagnosis of monogenic disorders using maternal plasma and targeted massively parallel sequencing is being investigated actively. We previously demonstrated that comprehensive genetic diagnosis of a Duchenne muscular dystrophy (DMD) patient is feasible using a single targeted sequencing platform. Here we demonstrate the applicability of this approach to carrier detection and noninvasive prenatal diagnosis.METHODS: Custom solution-based target enrichment was designed to cover the entire dystrophin ( DMD ) gene region. Targeted massively parallel sequencing was performed using genomic DNA from 4 mother and proband pairs to test whether carrier status could be detected reliably. Maternal plasma DNA at varying gestational weeks was collected from the same families and sequenced using the same targeted platform to predict the inheritance of the DMD mutation by their fetus. Overrepresentation of an inherited allele was determined by comparing the allele fraction of 2 phased haplotypes after examining and correcting for the recombination event.RESULTS: The carrier status of deletion/duplication and point mutations was detected reliably through using a single targeted massively parallel sequencing platform. Whether the fetus had inherited the DMD mutation was predicted correctly in all 4 families as early as 6 weeks and 5 days of gestation. In one of these, detection of the recombination event and reconstruction of the phased haplotype produced a correct diagnosis.CONCLUSIONS: Noninvasive prenatal diagnosis of DMD is feasible using a single targeted massively parallel sequencing platform with tiling design.
机译:背景:正在积极研究使用母体血浆和靶向大规模平行测序对单基因疾病进行非侵入性产前诊断。我们先前证明,使用单个靶向测序平台对杜氏肌营养不良症(DMD)患者进行全面的遗传诊断是可行的。在这里,我们证明了这种方法在载体检测和无创产前诊断中的适用性。方法:基于定制解决方案的目标富集被设计为覆盖整个肌营养不良蛋白(DMD)基因区域。使用来自4对母亲和先证者对的基因组DNA进行靶向大规模平行测序,以测试是否可以可靠地检测出载体状态。从相同的家庭中收集不同孕周的孕妇血浆DNA,并使用相同的靶向平台进行测序,以预测其胎儿对DMD突变的遗传。在检查并校正重组事件后,通过比较2个阶段单倍型的等位基因部分来确定遗传等位基因的过量表达。结果:通过使用单个靶向大规模平行测序平台,可靠地检测了缺失/重复和点突变的携带者状态。早在怀孕6周和5天时,所有4个家庭都可以正确预测胎儿是否遗传了DMD突变。其中之一是重组事件的检测和分阶段单倍体的重建产生了正确的诊断。结论:使用带有贴片设计的单个靶向大规模平行测序平台,DMD的无创产前诊断是可行的。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号